We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4540:TSETsumura & Co. Analysis

Data as of 2026-03-15 - not real-time

¥3,836.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Tsumura & Co. is trading at ¥3,836, sitting just below its 200‑day SMA of ¥3,750 but under both the 20‑day (¥4,020) and 50‑day (¥4,081) averages, indicating a short‑term pull‑back within a longer‑term uptrend. The RSI of 34.7 suggests the stock is oversold, yet the MACD remains in a bearish configuration and the price hovers near the identified support of ¥3,824, with resistance around ¥4,230. Market sentiment is in “Greed” territory (Fear‑Greed Index 72.9), and the low beta of 0.06 points to minimal market‑wide volatility, though the 30‑day volatility of roughly 22% and a max drawdown near 26% signal notable price swings.
Fundamentally, the company delivers a solid 15.9% revenue growth and a PE of 10.6, far below the industry average of 26.2, but a DCF‑derived fair value of ¥2,928 implies the current price is overvalued by about 19%. The dividend yield of 3.75% with a 37% payout ratio is attractive, yet negative free cash flow and a high debt‑to‑equity ratio (~40) raise concerns about long‑term sustainability. Overall, the stock presents a blend of short‑term technical pressure and long‑term growth potential, tempered by valuation and cash‑flow considerations.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near immediate support level
  • Bearish MACD histogram
  • RSI indicating oversold condition but limited upside

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong revenue growth of ~16%
  • Attractive dividend yield relative to peers
  • Current price exceeds DCF fair value, limiting upside

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Robust top‑line growth trajectory
  • Consistent dividend payout with moderate payout ratio
  • Industry PE significantly higher, suggesting relative undervaluation

Key Metrics & Analysis

Financial Health

Revenue Growth15.90%
Profit Margin15.31%
P/E Ratio10.6
ROE9.26%
ROA4.51%
Debt/Equity39.98
P/B Ratio0.9
Op. Cash Flow¥15.4B
Free Cash Flow¥-39473250304
Industry P/E26.2

Technical Analysis

TrendNeutral
RSI34.7
Support¥3,824.00
Resistance¥4,230.00
MA 20¥4,020.15
MA 50¥4,081.12
MA 200¥3,750.29
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Fair Value¥2,928.20
Target Price¥4,560.00
Upside/Downside18.87%
GradeOvervalued
TypeGrowth
Dividend Yield3.75%

Risk Assessment

Beta0.06
Volatility22.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.